Fastly’s Near-Term Risks Include Challenges with Top Customers, Analyst Expresses Concern
Analyst downgrades Fastly Inc from Buy to Underperform and lowers price target, citing near-term risks and decelerating growth in largest customers.
Analyst Doubts Macerich’s New CEO Strategy, Can They Turn Things Around?
Macerich Co (NYSE: MAC) downgraded & reduced price target by Piper Sandler. Reported Q1 sales of $208.783M & FFO of $0.33. New CEO appointed & withdrew FY24 guidance. Analyst skeptical of turnaround strategy, lowers FFO estimates for FY24 & FY25.
Paramount Could Be Worth $4 Or $14 Per Share In Deal, Analyst Says: ‘We Prefer To Sit This One Out’
A short earnings call and lack of updates from Paramount has analysts questioning what's next and encouraging caution to investors.
Mobileye Global Hit By Surprise EV Slowdown; This Analyst Turns Bearish
Mobileye Global reported a 48% year-on-year decline in revenues for the first quarter.
Meta’s Q1 Earnings: Analysts Say Support Its AI Strategy, ‘Use Meta As A Source Of Funds,’ Question Long-Term Value
Meta Platforms reported Q1 2024 earnings. Analysts have mixed views, with some optimistic about Meta's focus on AI and the Metaverse, while others recommend selling the stock. Wedbush favors Google, while Needham suggests using Meta as a source of funds.
Boeing Will Deliver Q1 Earnings While At Center Of Air Safety Scandal: ‘Everybody Wants Boeing To Succeed’
Boeing's earnings call this week will be closely watched as the company faces scandals and legal issues, causing a 32.5% drop in stock since January.
Nasdaq 100 Breaks 3-Day Losing Streak As Tech Stocks Rebound Ahead Of Earnings Week
Tech stocks rebound as Nasdaq 100 gains 1.5% and prepares for big earnings week from giants like Tesla, Microsoft, and Alphabet. UBS cautions on sector.
Stocks Edge Higher As Earnings Provide Support, Tesla Sinks To 15-Month Lows, Bitcoin Rebounds: What’s Driving Markets Thursday?
Stocks surged higher on Thursday, with the S&P 500 index aiming to snap a four-day losing streak as investors assess the latest wave of corporate earnings.
Analysts Question Commercial Viability of Marinus’ IV Ganaxolone After Interim Analysis Miss
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
What’s Going On With AvidXchange Stock Monday?
Goldman Sachs analyst downgraded AvidXchange Holdings from Neutral to Sell and decreased price target due to high stock price and competition concerns.